QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
Summary
Financing supports clinical activities for Companys two lead programs in ALS and pipeline developmentCAMBRIDGE, Mass., March 9, 2023 /PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million. "This financing round recognizes our scientific track record and will help us advance the clinical development of our two lead programs in ALS and robust pipeline through near-term value-creating milestones. ""QurAlis stands out as a leader in the field of neurodegenerative diseases with its next-generation precision medicines and genetically validated targets," said Philip Scheltens, M.D., Ph.D., head, EQT Life Sciences LSP Dementia Fund. "We are extremely excited to join this distinguished group of investors supporting this world-class team to advance what we believe could become life-changing treatments for patients and their families. QurAlis proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations.